• Profile

Ruxolitinib cream in the treatment of cutaneous lichen planus: A prospective, open-label study

Journal of Investigative Dermatology Feb 10, 2022

Findings of this small pilot study demonstrate high effectiveness of topical ruxolitinib in treating cutaneous lichen planus (LP). In transcriptomic analysis, LP was corroborated as an interferon-driven disease and downregulation of interferon-stimulated genes was shown to be correlated with disease response.

  • Ruxolitinib is a Janus kinase 1/2 inhibitor that blocks signal transduction of interferon-gamma, an important cytokine implicated in the pathogenesis of cutaneous LP.

  • This prospective phase II study included 12 patients with cutaneous LP who were instructed to apply topical ruxolitinib twice daily for 8 weeks.

  • Total lesion count reduced by a median of 50 lesions (interquartile range 25, 723; p<0.001).

  • At week 4, there was a decrease in modified Composite Assessment of Index Lesion Severity scores by a mean difference of 7.6 (standard deviation 8.8, p=0.016) between index treated and control lesions.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen